Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
2020 Year in Review - AML
Leukemia
Escalated Dosing Schedules of CC-486 Effective for Patients Experiencing First AML Low Blast Count Relapse
Read More
Leukemia
Gilteritinib + Azacitidine or Azacitidine Alone in Patients with Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia
Read More
Leukemia
,
Venetoclax
Comparative Effectiveness of Glasdegib or Venetoclax in Combination with Low-Dose Cytarabine Using Simulated Treatment Comparisons
Read More
Leukemia
,
Venetoclax
Phase 1b/2 Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies
Read More
Leukemia
Safety and Efficacy of Decitabine + Ipilimumab in Relapsed/Refractory MDS/AML in Posttransplant or Transplant-Naïve Settings
Read More
Leukemia
The First-in-Class Anti-CD47 Antibody Magrolimab + Azacitidine Is Well-Tolerated and Effective in Patients with AML
Read More
Leukemia
,
Venetoclax
Venetoclax Added to Cladribine plus Low-Dose Ara-C Alternating with 5-Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia
Read More
Leukemia
MBG453 in Combination with Hypomethylating Agents in Patients with High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Read More
Leukemia
,
Venetoclax
Phase 2 Study of CPX-351 plus Venetoclax in Patients with Acute Myeloid Leukemia
Read More
Leukemia
,
Venetoclax
Decitabine + Venetoclax Compared with Intensive Chemotherapy in AML: A Propensity Score–Matched Analysis
Read More
1
2
3
Page 2 of 3
Results 11 - 20 of 30
